NCT05315258
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05315258
Title Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma (TebeMRD)
Acronym TebeMRD
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Oxford
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR

Facility Status City State Zip Country Details
Cambridge University Hospitals NHS Foundation Trust (Screening only) Cambridge United Kingdom Details
The Beatson West of Scotland Cancer Centre Glasgow United Kingdom Details
The Clatterbridge Cancer Centre Liverpool United Kingdom Details
University College London Hospital London United Kingdom Details
The Christie Hospital Manchester United Kingdom Details
Mount Vernon Cancer Centre Middlesex United Kingdom Details
Newcastle upon Tyne Hospitals NHS Foundation Trust Newcastle United Kingdom Details
Churchill Hospital, Oxford University Hospitals NHS Trust Oxford OX3 7LE United Kingdom Details
Sheffield Teaching Hospitals NHS Foundation Trust (Screening only) Sheffield United Kingdom Details
University Hospital Southampton NHS Foundation Trust Southampton United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field